A5052428116- Cervical Cancer and HPV Research
- Hepatitis B Virus Studies
- Genital Health and Disease
- Acute Myocardial Infarction Research
- Reproductive tract infections research
- Mosquito-borne diseases and control
- COVID-19 Clinical Research Studies
- Cardiac Health and Mental Health
- COVID-19 and healthcare impacts
- Innovations in Medical Education
- COVID-19 and Mental Health
- Gastrointestinal disorders and treatments
- Antiplatelet Therapy and Cardiovascular Diseases
- Colorectal and Anal Carcinomas
- Venomous Animal Envenomation and Studies
- Rabies epidemiology and control
- Streptococcal Infections and Treatments
- Blood Pressure and Hypertension Studies
- Esophageal and GI Pathology
- Venous Thromboembolism Diagnosis and Management
- Heart Failure Treatment and Management
- Animal Virus Infections Studies
- Malaria Research and Control
- Medication Adherence and Compliance
- Workplace Violence and Bullying
Hospital Universitario Río Hortega
2024
Hospital Regional Universitario de Málaga
2023
Instituto Cardiovascular de Buenos Aires
2022
China Classification Society
2022
Consejo Nacional de Investigaciones Científicas y Técnicas
2022
National University of Comahue
2022
Universidad del Rosario
2008-2021
Takeda (United States)
2021
Mayo Clinic in Florida
2021
WinnMed
2021
Human papillomavirus types 16 (HPV-16) and 18 (HPV-18) cause approximately 70% of cervical cancers worldwide. A phase 3 trial was conducted to evaluate a quadrivalent vaccine against HPV 6, 11, 16, (HPV-6/11/16/18) for the prevention high-grade lesions associated with HPV-16 HPV-18.
A phase 3 trial was conducted to evaluate the efficacy of a prophylactic quadrivalent vaccine in preventing anogenital diseases associated with human papillomavirus (HPV) types 6, 11, 16, and 18.In this randomized, placebo-controlled, double-blind involving 5455 women between ages 16 24 years, we assigned 2723 receive 2732 placebo at day 1, month 2, 6. The coprimary composite end points were incidence genital warts, vulvar or vaginal intraepithelial neoplasia, cancer cervical adenocarcinoma...
Human papillomavirus (HPV)-6/11/16/18 vaccine reduces the risk of HPV-6/11/16/18-related cervical intraepithelial neoplasia (CIN) 1-3 or adenocarcinoma in situ (AIS). Here, its impact on CIN1-3/AIS associated with nonvaccine oncogenic HPV types was evaluated.We enrolled 17,622 women aged 16-26 years. All underwent cervicovaginal sampling and Pap testing at regular intervals for up to 4 genotyping performed biopsy samples, histological diagnoses were determined by a pathology panel. Analyses...
The impact of the prophylactic vaccine against human papillomavirus (HPV) types 6, 11, 16, and 18 (HPV6/11/16/18) on all HPV-associated genital disease was investigated in a population that approximates sexually naive women they were "negative to 14 HPV types" mixed HPV-exposed -unexposed (intention-to-treat group).This analysis studied 17 622 aged 15-26 years who enrolled one two randomized, placebo-controlled, efficacy trials for HPV6/11/16/18 (first patient December 28, 2001, studies...
Objectives To evaluate the prophylactic efficacy of human papillomavirus (HPV) quadrivalent vaccine in preventing low grade cervical, vulvar, and vaginal intraepithelial neoplasias anogenital warts (condyloma acuminata).
Quadrivalent human papillomavirus (HPV) vaccine has been shown to provide protection from HPV 6/11/16/18-related cervical, vaginal, and vulvar disease through 3 years. We an update on the efficacy of quadrivalent against high-grade lesions based end-of-study data three clinical trials. Additionally, we stratify by several baseline characteristics, including age, smoking status, Papanicolaou (Pap) test results. A total 18,174 females ages 16 26 years were randomized allocated into one trials...
To determine the effect of human papillomavirus (HPV) quadrivalent vaccine on risk developing subsequent disease after an excisional procedure for cervical intraepithelial neoplasia or diagnosis genital warts, vulvar neoplasia, vaginal neoplasia.
Healthcare workers exposed to coronavirus (COVID-19) may not have adequate access personal protective equipment (PPE), safety procedures, and diagnostic protocols. Our objective was evaluate the reality perceptions about among healthcare in Latin America. This is a cross-sectional, online survey-based study administered 936 professionals America from 31 March 2020 4 April 2020. A 12-item structured questionnaire developed. total of completed survey. Of them, 899 (95.1%) were physicians, 28...
BackgroundWe evaluated the impact of a quadrivalent human papillomavirus (HPV) vaccine on infection and cervical disease related to 10 nonvaccine HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59) associated with >20% cancers. The population included HPV-naive women preexisting and/or HPV-related at enrollment MethodsPhase 3 efficacy studies enrolled 17,622 aged 16–26 years. Subjects underwent cervicovaginal sampling Pap testing day 1 then 6–12-month intervals for up 4 typing was performed...
ObjectiveIn the quadrivalent (types 6/11/16/18) HPV vaccine (GARDASIL®/SILGARD®) clinical program, 73% of women aged 16-26 were naïve to all types. In these women, prophylactic administration was highly effective in preventing 6/11/16/18-related cervical disease. Of remaining 15% had evidence past infection with one or more types (seropositive and DNA negative) at time enrollment. Here we present an analysis this group determine efficacy 6/11/16/18 against new external anogenital disease...
Abstract Background: We estimated the prevalence and incidence of 14 human papillomavirus (HPV) types (6/11/16/18/31/33/35/39/45/51/52/56/58/59) in cervicovaginal swabs, attribution these HPV cervical intraepithelial neoplasia (CIN), adenocarcinoma situ (AIS), using predefined algorithms that adjusted for multiple-type infected lesions. Methods: A total 10,656 women ages 15 to 26 years 1,858 24 45 were enrolled placebo arms one three clinical trials a quadrivalent vaccine. cumulative...
We evaluated the overall agreement between colposcopically directed biopsies and definitive excisional specimens within context of three clinical trials. A total 737 women aged 16-45 who had a cervical biopsy taken 6 months before their therapy were included. Per-protocol, colposcopists to also obtain representative immediately therapy. Using adjudicated histological diagnoses, initial same day correlated with surgically excised specimens. The therapy, diagnoses was 42% (weighted kappa =...
More than 500 million people worldwide live with cardiovascular disease (CVD). Health systems today face fundamental challenges in delivering optimal care due to ageing populations, healthcare workforce constraints, financing, availability and affordability of CVD medicine, service delivery. Digital health technologies can help address these challenges. They may be a tool reach Sustainable Development Goal 3.4 reduce premature mortality from non-communicable diseases (NCDs) by third 2030....
Abstract Background: We describe transition probabilities for incident human papillomavirus (HPV) 16/18/31/33/35/45/52/58/59 infections and cervical intraepithelial neoplasia (CIN) 1 lesions. Methods: Women ages 16 to 23 years underwent cytology swab PCR testing HPV at approximately 6-month intervals up 4 in the placebo arm of an vaccine trial. The cumulative proportion with diagnosed CIN, clearing (infection undetectable), or persisting without were estimated. Results: Most cleared,...
Abstract Background: We describe the incidence and duration of cervical human papillomavirus (HPV) infection episodes along with risk reappearance following a period nondetection. Methods: Women (1,788) ages 16 to 23 years underwent cytologic testing PCR-based swab samples for HPV DNA (HPV-16/18/31/33/35/45/52/58/59) at ∼6-month intervals up 4 in context phase 3 clinical trial (placebo arm). type–specific rates were estimated per 100 person-years. Duration type-specific nondetection using...
Abstract The prevalence of HPV infection in Latin America is among the highest world. A quadrivalent (types 6/11/16/18) human papillomavirus L1 virus‐like‐particle vaccine has been shown to be 95–100% effective preventing 6/11/16/18‐related cervical and genital disease women naïve types. total 6,004 female subjects aged 9–24 were recruited from Brazil, Mexico, Colombia, Costa Rica, Guatemala Peru. Subjects randomized immunization with intramuscular (deltoid) injections or placebo at...
A 9-valent human papillomavirus-6/11/16/18/31/33/45/52/58 (9vHPV) vaccine extends coverage to 5 next most common oncogenic types (31/33/45/52/58) in cervical cancer versus quadrivalent HPV (qHPV) vaccine. We describe efficacy, immunogenicity, and safety Asian participants (India, Hong Kong, South Korea, Japan, Taiwan, Thailand) from 2 international studies: a randomized, double-blinded, qHPV vaccine-controlled efficacy study (young women aged 16-26 years; NCT00543543; Study 001); an...